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Abstract: FAD synthase (FADS, or FMN:ATP adenylyl transferase) coded by the FLAD1 gene is the
last enzyme in the pathway of FAD synthesis. The mitochondrial isoform 1 and the cytosolic isoform
2 are characterized by the following two domains: the C-terminal PAPS domain (FADSy) performing
FAD synthesis and pyrophosphorolysis; the N-terminal molybdopterin-binding domain (FADHy)
performing a Co++/K+-dependent FAD hydrolysis. Mutations in FLAD1 gene are responsible
for riboflavin responsive and non-responsive multiple acyl-CoA dehydrogenases and combined
respiratory chain deficiency. In patients harboring frameshift mutations, a shorter isoform (hFADS6)
containing the sole FADSy domain is produced representing an emergency protein. With the aim
to ameliorate its function we planned to obtain an engineered more efficient hFADS6. Thus, the
D238A mutant, resembling the D181A FMNAT “supermutant” of C. glabrata, was overproduced
and purified. Kinetic analysis of this enzyme highlighted a general increase of Km, while the kcat
was two-fold higher than that of WT. The data suggest that the FAD synthesis rate can be increased.
Additional modifications could be performed to further improve the synthesis of FAD. These results
correlate with previous data produced in our laboratory, and point towards the following proposals
(i) FAD release is the rate limiting step of the catalytic cycle and (ii) ATP and FMN binding sites are
synergistically connected.
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1. Introduction
The riboflavin (Rf) derived FMN and FAD cofactors play a pivotal role in cell economy ensuring
the functionality of the flavoproteome, mainly localized in mitochondria [1,2]. Consistent with
the crucial role of flavins and flavoenzymes in cell life, several diseases, including neuromuscular
and neurological disorders are linked to flavin-dependent enzyme deficiency or impairment in Rf
homeostasis in humans and experimental animals. These disorders, in some cases, can be cured
with high doses of Rf, as the two Rf-responsive (RR) disorders Brown–Vialetto van Laere syndrome
(BVVLS) [3,4] and RR-multiple acyl-CoA dehydrogenase deficiency (RR-MADD) [5–7]. In mammalian
cells, Rf is taken up via translocators (SLC52A1-3, also named RFVT1-3) [8,9] and converted into FMN
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and FAD via the sequential action of Rf kinase (RFK, EC 2.7.1.26) and FAD synthase or FMN-ATP
adenylyl transferase (FADS, EC 2.7.7.2).
The only gene identified for coding functional FAD synthases in humans is FLAD1 gene (GenBank,
A. N. DQ458779, [10]) localized on chromosome 1, which is orthologue of flad-1 in C. elegans, [11], Fad1
in S. cerevisiae [12] and FMNAT in C. glabrata [13]. The structures of FADSs from yeast, but not that of
the human orthologue, have been solved [13,14].
The FLAD1 gene in humans generates different alternative transcript variants, with unknown
differential expression profile, producing protein isoforms, only in part characterized, which have
different subcellular localization [15] and domain organizations.
The most abundant variant in all the tissues and cells tested so far, is isoform 2 (NM_201398.3 in
NCBI GenBank), which corresponds to a cytosolic enzyme of 490 amino acids [15]. The FADS or FMN-AT
module of this protein is localized in the C-terminus of the protein; it contains a phosphoadenosine
5-phosphosulfate (PAPS) reductase domain and it is fused with a molybdopterin binding resembling
(MPTb) domain located in the N-terminus [16,17].
FAD synthesis catalyzed by hFADS2 follows a bi-bi ordered kinetics with ATP entering prior to
FMN and pyrophosphate released before FAD [17]. This enzyme contains 10 cysteines, some of which
are relevant for catalysis; two of them are stably reduced (C139 and C241, one for each protein domain),
four are implicated in stable disulfide bridges (C399 to C402, C303 to C312, both in the PAPS domain),
and the other four are forming redox sensitive disulfides (C39 to C50; C440 to C464) [18].
Following the discovery that hFADS2 is a bifunctional enzyme, with the N-terminal domain
working as a Co2+-dependent FAD hydrolase, the two domains of the protein were renamed as FADHy
and FADSy, functionally corresponding to E.C. 3.6.1.18 and E.C. 2.7.7.2, respectively [19,20]. FADHy
is also present in the other three isoforms of the protein reported in the NCBI GenBank (FLAD1
isoform 1, NM_025207.5; FLAD1 isoform 3, NM_001184891.2; and FLAD1 isoform 4, NM_001184892.2).
Nonetheless, it is indeed absent in the FAD1p yeast counterparts and, more interestingly, in another
human isoform not yet annotated as FADS, but reported as CRA_d in NCBI and known as hFADS6.
The isoform hFADS6 is a 320-residue long protein, containing the sole FADSy domain, whose
corresponding transcript was recently described in the frame of studying FLAD1 mutations leading to
RR-MADD [7]. The relevance of this novel isoform lies in its ability to ensure FAD supply to patients
carrying frameshift mutations in exon 2 of the FLAD1 gene and, for this reason, it has been named
an “emergency protein” for MADD patients. When produced in E. coli and purified at homogeneity,
hFADS6 behaves as a yellow monomer, able to tightly, but not covalently, bind FAD. Recombinant
hFADS6 is more stable than hFADS2 and is able to perform FAD synthesis starting from FMN and
ATP. As expected, it is not able to perform FAD hydrolysis [21]. The molecular features of this novel
natural form well correlate with those of a previously produced artificial construct, lacking the first 231
residues of hFADS2, which per se can fold and catalyze the FAD synthesis reaction [22]. Therefore,
this novel isoform of FAD forming enzymes is, in our opinion, a good model to address remaining
challenges in the catalytic behavior of the FAD synthesis reaction in humans, as compared with the
our deeper understanding of the yeast orthologues [13,14], from which structure the human protein
was modeled [21]. The more striking point concerning the catalytic cycle of FAD forming enzyme
concerns the observation that the turn-over number of the reaction, as catalyzed by hFADS2, is quite
low (0.069 ± 0.011 s−1), with FAD release being the limiting step of the over-all reaction [23]. This
apparently sounds strange for a protein which is expected to be devoted to FAD delivery. We postulate
that redox events or protein–protein interaction in a sort of chaperoning process may promote cofactor
delivery to cognate apo-flavoprotein [17,23].
The aim of this work was to confirm the proposed mechanism by proving that lowering the
FAD affinity toward the catalytic site (i.e., facilitating FAD release) results in increasing the turn-over
number of the FAD forming reaction. To obtain these results we took into account studies on Candida
glabrata FMN-AT (CgFMN-AT) [24] that identified a cryptic residue, precisely D181, whose mutation to
Ala resulted in an increase of the Vmax, and therefore it was named “super-mutant”. The orthologous
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residue in the human enzyme is D238. We investigate, here, the effects of the D238A mutation on
hFADS6 steady-state activity and binding capability to confirm our hypothesis that a weak FAD
binding to the active site could led to an increased rate of synthesis. The possible final goal of this
study is to open a perspective towards increasing the emergency enzyme activity in patients suffering
for FLAD1 mutations.
2. Results
2.1. Homology Model of D238A-hFADS6
The amino acid sequences of WT and D238A mutant hFADS6 were aligned by Clustal Omega
software with the FMN-AT protein Q6FNA9 of C. glabrata. The alignment presented in Figure 1
highlights not only a high percentage identity (about 32%) between the human and the yeast proteins,
but also confirms that D238 of hFADS6 corresponds to D181 of the yeast orthologue and that it is part
of the flavin binding motif.
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Figure 1. Sequence alignment of CgFMN-AT (Q6FNA9), hFADS6, and hFADS6D238A. The protein
sequences were aligned by Clustal Omega software. D181 of the yeast protein, D238 of the hFADS6,
and A238 in the mutant are shadowed in grey. Amino acids forming the flavin binding motif are
highlighted by boxes.
Due to the lack of suitable templates for modeling the N-terminus (amino acids 1 to 108) of
hFADS6, an ab initio strategy was previously adopted to obtain its three-dimensional (3D) structural
model [21]. FAD was then inserted in the active site according to the structure of CgFMN-AT (3G6K)
as described in Materials and Methods. Figure 2 clearly shows a reduced steric hindrance upon
substitution of D238 with A. However, the major reason for varied FAD binding and release kinetics
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should be the loss of the dipole interaction between the Asp-carboxylate group and the N(3)H-FAD,
which most affects FAD binding.
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Figure 2. Modeling and FAD docking of hFADS6: (a) Ri bon representation of hFADS6 modeled as
described in [21]. FAD transferred in the active site from PDB ID: 3G6K and represented as yellow
licorice c lored by h teroatom type. (b,c) Zoom into the binding site of the isoalloxazine moiety of
FAD. Amino acids involved in isoalloxazine binding are colored in pink. D238 in the WT (b) and A238
in the mutant (c) are rendere as green licorice colored by heteroatom type.
2.2. Cloning, Expression, and Purification of the D238A-hFADS6 Isoform
The D238A mutant of the hFADS6 was constructed as described in Materials and Methods. The
protein overexpressed in E. coli showed similar electrophoretic mobility to that of the WT [21] when
purified by Ni-chelating chromatography, i.e., an apparent molecular mass of about 35 kDa. This
value was compatible with the theoretical mass derived from the tagged sequence of the expressed
polypeptide (38.222 kDa, Figure 3).
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Figure 3. Protein fractions obtained by i2+-chelating chro atography ere separated by S S–P E
on 12% polyacrylamide gel and stained with Coomassie blue. Lane 1, insoluble fraction of IPTG-induced
cell lysate (6 µg); lane 2, soluble fraction of IPTG-induced cell lysate (28 µg); lane 3, first flow-through
fraction (19 µg), lane 4, proteins eluted with 50 mM imidazole (13 µg), lane 5, first fraction of proteins
eluted with 100 mM imidazole (2 µg), lane 6, second fraction of proteins eluted with 100 mM imidazole
(3 µg), lane 7, third fraction of proteins eluted with 100 mM imidazole (2 µg); lane 8, first fraction of
proteins eluted with 250 mM imidazole (5 µg); lane 9, second fraction of proteins eluted with 250 mM
imidazole (1 µg); and lane 10, molecular mass markers.
The overexpressed protein was recovered in the soluble fraction of the cell lysate and was used for
spectrophotometric analysis and compared with the WT protein. The spectrum of the most abundant
purified mutant protein fraction (fraction 8), whose purity is higher than 98%, is shown in Figure 4.
An absorbance peak at 274 nm was observed, but surprisingly, no other peaks were present at higher
absorption values. As the control, the WT hFADS6 spectrum was shown, presenting two additional
minor peaks, at 350 and 450 nm, typical of oxidized FAD (Figure 4). From the absorbance value at
280 and 450 nm a ratio FAD/hFADS6 of 0.43 was calculated, as reported in [21], and thus indicating
the presence of some apoprotein. The spectra of fractions 5, 6, 7, and 9 showed the same features as
fraction 8. The spectral features of the D238A mutant hFADS6 indicated that this protein does not
stabilize the strong binding of flavins.
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Figure 4. Absorption spectra of hFADS6 and D238A-hFADS6 purified to homogeneity. The spectra
of WT hFADS6 (8.6 µM, grey dotted line) and of D238A-hFADS6 (9.7 µM, black line) were recorded
in 40 mM HEPES/Na, 5 mM β-mercaptoethanol, pH 7.4. The protein concentration was measured as
indicated in [21].
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2.3. Kinetics of the D238A hFADS6
The mutant protein was characterized in terms of kinetics to uncover possible variations of
interactions with the substrates or the effectors and inhibitors. Figure 5 shows the response of the
mutant to Mg2+, which is a known effector of hFADSs, including the hFADS6 isoform [21,23]. The
presence of Mg2+ is also essential for activity in the mutant. However, a different behavior was
observed. The AC50 (half maximum activation constant) of Mg2+ is quite higher in the mutant than
in the WT. Its value 3.5 ± 0.9 mM is twenty-fold that of the WT. Moreover, a higher value of Vmax is
measured in the case of the mutant. Another distinctive feature is the inhibition observed at higher
Mg2+ concentrations, which was not present in the WT. The effect of Hg2+ was also studied because
this heavy metal typically inhibits the WT protein due to interaction with the Cys residues [18,21,23].
Differently from the case of Mg2+, the effect of Hg2+ on the mutant was very similar to that on the
WT enzyme.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 6 of 17 
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FAD synthesi rate, catalyzed by purified hFADS6 (open circle, 10 µg, 0.26 nmoL) or D238A-hFADS6
(closed circle, 3.2 µg, 0.08 nmol), was flu rimetrically measured at 37 ◦C in 2 mL of 50 mM Tris/HCl pH
7.5, in the resence of 2 µM or 3 µM FMN, respectively, 100 µM ATP, 5 mM MgCl2 and of the given
HgCl2 conce trations. The values of V0 are reported as nmol min−1 mg−1 (a) and as percentages of the
maximum rate (b) arbitrarily set to 100%. Data points are fitted according to the Michaelis–Menten
equation (a) and according to the IC50 equation (b) with Grafit 3.0 software.
Then, the dependence of the FAD synthesis rate on the concentrations of the main substrates
FMN and ATP was studied in the presence of saturating concentration of the counter-substrate, i.e.,
ATP and FMN, respectively. As shown in Figure 6a, dependences on the ATP concentration for the
WT and the mutant were quite different. Both the Km and the Vmax increased in the mutant. The
Km for ATP increased from 6.9 ± 0.5 µM (WT) to 44 ± 4 µM (mutant). The Vmax increased from
79 ± 1 (WT) to 145 ± 5 nmol min−1 mg−1 protein. The derived kcat of the mutant was 0.093 ± 0.003 s−1
(5.6 ± 0.2 min−1) which is about double than that of the WT 0.050 ± 0.001 s−1 (3.0 ± 0.1 min−1) [21]. To
graphically highlight the difference in Km, the same data were expressed as percentage of the Vmax
(Figure 6a’). A similar behavior was observed when measuring the dependence of the reaction rate on
FMN concentrations. Again, the Km for FMN and the Vmax increased in the mutant (Figure 6b). The Km
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for FMN increased from 0.13 ± 0.01 µM (WT) to 1.3 ± 0.3 µM (mutant). The Vmax increased from 74 ± 1
(WT) to 162± 12 nmol min−1 mg−1 protein (mutant). The derived kcat of the mutant was 0.103 ± 0.007 s−1
(6.2 ± 0.5 min−1) which is about twice that of the WT 0.047 ± 0.001 s−1 (2.9 ± 0.1 min−1) [21], very
similar to that obtained for the ATP kinetics. In this case, the same data were represented as percentage
of the Vmax (Figure 6b’). Table 1 summarizes the kinetic comparison between WT and D238A hFADS6.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 7 of 17 
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in the mutant, while the Vmax remained very similar. Even though an increase of Km for FAD (0.045 ± 
0.008 µM) is clearly evident in the mutant, the Km value for the WT could not be accurately measured 
due to both instrumental limitations and to the presence of tightly bound FAD in the active site of 
the WT protein [21,23]. Therefore, to measure a reliable Km of FAD for the WT, the apo-enzyme was 
prepared autocatalytically, i.e., by incubating the purified protein at 37 °C for 10 min in the presence 
of MgCl2 and NaPPi and in the absence of externally added FAD, allowing the reverse reaction to 
occur using the endogenous bound FAD. At this stage, after endogenous FAD conversion to FMN, 
external FAD was added, and the reverse reaction started (Figure 7c). Under this condition, in which 
the reaction rate could be measured, being much lower than in the case of the holo-enzyme and, 
hence, an accurate value of Km could be calculated. As shown in Figure 7d, the Km for FAD of the WT 
Figure 6. Fluorimetric evidence of FAD synthesis. The FAD synthesi reaction was started by the
addition of purified recombina t proteins (hFADS6 open cir le or D238A-hFADS6 closed cir le) and
measured by the initial rate of fluorescence decrease (λ excitation = 450 nm and λ emission = 520 nm).
V0 was expressed as nmol min−1 mg−1 (a,b) an as percentage of the Vmax value (a’,b’) set arbitrarily
to 100%. Data points are fitted according to the M chaelis–Menten equation with Grafit 3.0 software.
(a) ATP concentration dependence. FAD synthesis rate, ca alyzed by purified hFADS6 (open circle,
10 µg, 0.26 nmoL) or D238A-hFADS6 (closed circle, 4.2 µg, 0.11 nmoL), was fluorimetrically easured
at 37 ◦C in 2 mL of 50 mM Tris⁄H l pH 7.5, in the presence of 5 mM MgCl2, 2 µM or 3 µM F N,
respectively, and of the giv n ATP concentrations. (b) FMN conce tration dependence. FAD synthesis
rate catalyzed by purified hFADS6 (open circle, 10 µg, 0.26 nmoL) or D238A-hFADS6 (closed circle,
3.9 µg, 0.10 nmoL) was fluorimetrically measured at 37 ◦C in 2 mL of 50 M Tris⁄HCl pH 7.5, in the
presence of 5 mM MgCl2, 100 µM ATP, and of the given FMN concentrations.
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520 nm). Data points are fitted according to the Michaelis–Ment n equation with Grafit
3.0 software. (a) NaPPi concentration ependence. FAD cleavage (i.e., y phosporolysis) rate,
catalyzed by purified hFADS6 (open circle, 10 µg, 0.2 nmol) or 6His-D238A-hFADS6 (closed circle,
10 µg, 0.26 nmol), was measured fluorimetrically at 37 ◦C in 2 mL of 50 mM Tris ⁄ HCl pH 7.5, in the
presence of 5 mM gCl2, 0.5 µM FAD, and of the given NaPPi concentrations. (b) FAD conc tration
dependence. FAD cleavage (i.e., pyrophosporolysis) rate, catalyzed by purified hFADS6 (open circle,
10 µg, 0.26 nmol) or D238A-hFADS6 (closed circle, 10 µg, 0.26 nmoL), was measured fluorimetrically at
37 ◦C in 2 mL of 50 mM Tris ⁄ HCl pH 7.5, in the presence of 5 mM MgCl2, 1 mM NaPPi, and the given
FAD concentrations. (c) Exogenous FAD cleavage following endogenous FAD removal from hFADS6.
The reaction catalyzed by purified hFADS6 (5 µg, 0.13 nmoL) was followed at 37 ◦C in 2 L of 50
Tris⁄ Cl p 7.5, in the presence of 5 gCl2 and 1 aPPi until the fluorescence reached a
constant value corresponding to complete endogenous FAD conversion to F N (grey line). hen
indicated exogenous FAD (0.5 µM) was added to calculate the rate of pyrophosporolysis (black line).
(d) FAD concentration dependence of hFADS6 apo-form. FAD cleavage rate, catalyzed by apo-form of
hFADS6 (5 µg, 0.13 nmoL), was measured fluorimetrically at 37 ◦C in 2 mL of 50 mM Tris ⁄ HCl pH 7.5,
in the presence of 5 mM MgCl2, 1 mM NaPPi, and the given added FAD concentrations as described in
Material and Methods (paragraph 4.6.) and graphically explained in (c).
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Table 1. Comparison between Kms for substrates of hFADS6 and D238A-hFADS6. * The value was
obtained using the autocatalytically formation of apo-eznyme as described in Materials and Methods
and graphically explained in Figure 7c. Km values of the mutant are in bold
6His-hFADS6 6His-D238A-hFADS6
Forward reaction
Km FMN (µM) 0.13 ± 0.01 1.3 ± 0.3
Km ATP (µM) 6.9 ± 0.5 44 ± 4
Ac50 Mg2+ (mM) 0.15 ± 0.02 3.5 ± 0.9
Reverse reaction
Km PPi (mM) 0.042 ± 0.006 0.060 ± 0.008
Km FAD (µM) 0.0079 ± 0.0017 * 0.045 ± 0.008
The reverse reaction, i.e., pyrophosphorolysis was also revealed by using recombinant FADS
enzymes [21,23]. The kinetics of this reverse reaction was measured for the mutant in comparison
with the WT. In the reverse reaction, the Km for NaPPi (Figure 7a) and for FAD (Figure 7b) increased
in the mutant, while the Vmax remained very similar. Even though an increase of Km for FAD
(0.045 ± 0.008 µM) is clearly evident in the mutant, the Km value for the WT could not be accurately
measured due to both instrumental limitations and to the presence of tightly bound FAD in the active
site of the WT protein [21,23]. Therefore, to measure a reliable Km of FAD for the WT, the apo-enzyme
was prepared autocatalytically, i.e., by incubating the purified protein at 37 ◦C for 10 min in the presence
of MgCl2 and NaPPi and in the absence of externally added FAD, allowing the reverse reaction to
occur using the endogenous bound FAD. At this stage, after endogenous FAD conversion to FMN,
external FAD was added, and the reverse reaction started (Figure 7c). Under this condition, in which
the reaction rate could be measured, being much lower than in the case of the holo-enzyme and, hence,
an accurate value of Km could be calculated. As shown in Figure 7d, the Km for FAD of the WT was
derived from the curve of Figure 7d. Its value was 0.0079 ± 0.0017 µM. This data correlates well with
the data of Figure 7b, confirming that, indeed, the Km of the mutant is much higher.
Since some nucleotides have been proposed to affect the enzyme activity of FADS [20], we have
also tested the effect of GTP and NAD+ on the mutant activities. The D238A-hFADS6 was inhibited
by GTP and by NADH in analogy with the typical behavior of a FADS enzyme (Supplementary
Figure S1a,b).
2.4. Impact of the D238A Mutation in the Binding Kinetics of Flavinic Substrates
In the attempt to kinetically dissect the binding of substrates from the overall catalytic reaction
process we used stopped-flow spectrophotometry to evaluate the forward (ATP + FMN) and reverse
(PPi + FAD) reactions in both WT and D238A hFADS6. Binding and catalysis processes might
induce changes in the fluorescence of the flavin isoalloxazine; the first due to changes in its electronic
environment [25,26], and the second because of the lower FAD fluorescent yield. No relevant changes
in flavin fluorescence are detected when mixing WT or D238A hFADS6 with FMN, FAD, or a mixture
containing FMN and ADP. These results agree with isothermal titration calorimetry (ITC) lacking to
detect direct FMN binding and just envisaging slow direct binding of FAD (Supplementary Figure S2).
On the contrary, when introducing the stopped-flow mixtures, in addition to the flavin substrate, the
second substrate of the FMN-AT or FADpp activities, ATP or PPi, respectively, noticeably changes in
the fluorescence of the flavins are detected (Figure 8).
In mixtures containing substrates of the forward reaction, ATP and FMN, the relevant decrease
in the flavin fluorescence is indicative of internalization of the isoalloxazine or FMN transformation
into FAD. These observations also agree with ATP binding to the protein prior to FMN in the bi-bi
ordered kinetic mechanism reported for hFADSs [17]. Nonetheless, features for this fluorescence decay
also differ between WT and D238A hFADSs (Figure 8a). WT hFADS6 shows an initial biexponential
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fluorescence decay followed by a linear one. The first exponential decay has observed rate constants
(kobs1) in the low seconds range which depend linearly on the FMN concentration, while its amplitude
is concentration independent (Supplementary Figure S3a,b). kobs2 for the second exponential decay
indicate a slower process nearly FMN concentration independent, with amplitude increasing with FMN
concentration (Supplementary Figure S3a,b). Linear dependence of kobs1 on substrate concentration
indicates this process relates to FMN binding to the protein, and determines the kinetic constants for
FMN binding (kon = 3.4± 0.1µM−1 s−1) and dissociation (koff = 0.32± 0.001 s−1) for the WT hFADS6:ATP
complex, as well as a dissociation constant (KdFMN = koff/kon) for the ternary hFADS6::ATP:FMN
complex (Table S1). The derived KdFMN, 0.094 ± 0.004 µM, agrees well with the above derived KmFMN
for WT hFADS6. Features of the second exponential process suggest it might represent reorganization
of the initial complex to achieve the catalytic organization. Finally, the continuous and linear flavin
fluorescence decay established after the exponential processes fits well with the settlement of the
catalytic steady-state transformation of FMN into FAD, showing, in addition, rates in the ranges of
Vmax and kcat. When similarly evaluating D238A hFADS6, the exponential flavin fluorescence decays
related to FMN binding collapse in a single process that becomes hardly detectable, suggesting a
deleterious effect of the mutation in the isoalloxazine internalization within the protein. Nonetheless,
fluorescence decay related to FMN transformation into FAD follows similar traits to the WT ones
(Figure 8a). Kinetic parameters for FMN binding to D238A hFADS6:ATP are as a consequence difficult
to unambiguously quantify (Table S1), but data make clear that binding of FMN to the mutant is
considerably slower and less efficiently than to WT (Figure S3a). Collectively, these observations
further confirm that the D238A mutation has a deleterious effect in the FMN binding process.
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engineered improving its kcat as in the case of the lower eukaryotic organism. Although the kcat value 
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based on computational analysis (molecular dynamics) together with additional site-directed 
mutagenesis to obtain an engineered enzyme with optimized kinetics. 
On the basis of changes in both ATP and FMN Kms measured here in the forward reaction and 
of previous observations [17], the binding of the two substrates appears to be synergistic. 
Indeed, the extremely low Km for FAD, measured in the course of the reverse reaction, indicates 
the presence of a very stable bond between FAD. This is in agreement with the finding that size 
exclusion chromatography is not able to remove FAD from the protein [21,22]. However, the presence 
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but non-covalent interactions have been well described for the mitochondrial ADP/ATP binding to 
Figure 8. Dis ection of the kinetics of the substrates binding proces from the catalytic reaction by
stop ed-flow spectrophot metry. Normalized kinetic traces for the flavin fluorescenc evolution upon
mixi g the prot in with substrate for the (a) forwa d (ATP + FMN) and (b) rev rse (P i + FAD)
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100 nM of protei and 250 µM of either ATP (a) or PPi (b) in 50 mM HEPES/NaO , 10 mM MgCl2, pH
7.0, 5 mM β-mercaptoethanol. All concentrations are final after mixing.
When similarly evaluating the reverse reaction, kinetic traces for both WT and the D238A mutant
show an initial fluorescence exponential decay of small amplitude that is followed by a linear increase
of the signal (Figure 8b). We again deduce the kinetics for binding of FAD from the exponential decay,
while rates for the subsequent linear fluorescence increase relate well to steady-state kinetic parameters
for the transformation of FAD into FMN. Although the small amplitudes for FAD binding make it
difficult to accurately determine kobs values, both parameters show a dependence on the substrate
concentration (Supplementary Figure S3a,b). Errors in estimated kinetic parameters when using these
Int. J. Mol. Sci. 2019, 20, 6203 11 of 17
data are high, but obtained values are again indicative of the mutant binding FAD slower and weaker
than the WT (Supplementary Table S1 and Figure S3c,d).
3. Discussion
The substitution of the D238 residue with A in hFADS6, reproduces the previously described
mutation of the homologous residue of the Cg FMN-AT that generated an enzyme exhibiting a higher
rate of FAD production. The hFADS6 mutant shows similar kinetic changes. The data correlate well
with the high conservation of the FAD binding site of eukaryotic FAD synthesizing enzymes along the
different species as previously highlighted [16]. This work provides the first evidence that the human
FAD synthesizing domain, which corresponds to the hFADS6 enzyme isoform, can be engineered
improving its kcat as in the case of the lower eukaryotic organism. Although the kcat value increases,
currently, only two-fold, this result can be a promising starting point for further studies based on
computational analysis (molecular dynamics) together with additional site-directed mutagenesis to
obtain an engineered enzyme with optimized kinetics.
On the basis of changes in both ATP and FMN Kms measured here in the forward reaction and of
previous observations [17], the binding of the two substrates appears to be synergistic.
Indeed, the extremely low Km for FAD, measured in the course of the reverse reaction, indicates
the presence of a very stable bond between FAD. This is in agreement with the finding that size
exclusion chromatography is not able to remove FAD from the protein [21,22]. However, the presence
of a covalent linkage was previously excluded on the basis of the acidic treatment [23]. Similar strong
but non-covalent interactions have been well described for the mitochondrial ADP/ATP binding to
carboxyatractilosyde [27]. Indeed, a reliable Km value has only been measured in the present work
after using a strategy for removing the bound cofactor (see Figure 7d).
The residue 238 has a major role in this strong interaction. The molecular bases of the improved
synthesis rate rely in the correlation between the Km for the FAD and the increase in kcat. Indeed,
the increased Km derives by a weaker binding of the FMN or FAD to the enzyme active site. This
correlates well with the binding data. These experimental evidences confirm the hypothesis that a
labile binding allows a faster release of the newly formed cofactor, and hence an increase of the rate
of synthesis. The mechanism was firstly hypothesized in the case of the C. glabrata enzyme [24]. In
this work, in addition to confirming the kinetic data at the basis of the hypothesis, we provide further
evidences based on the variations of the binding after FAD conversion into FMN. Moreover, using
the stopped-flow procedure that allows dissecting the binding from the overall catalytic process we
provide evidences that the increase of Km observed in the mutant can be attributed mostly to a lower
binding affinity in the mutant. This could be the basis of a faster release of FAD.
On a structural point of view, the substitution of a hydrophilic residue (Asp) with a hydrophobic
one (Ala) weakens the bonds among the FAD molecule and the amino acid residues of the protein
active site. The weakening is explained at the molecular level by some structural changes. First,
putative hydrogen bonds that fixed FAD to the site are abolished upon substitution of Asp (which can
form hydrogen bonds) by Ala (whose side chain is hydrophobic). In addition, the decrease of the side
chain size of the 238 residues, resulting from substituting Asp by Ala, favors the release of the cofactor
to the external solvent (see Figure 2). This is in agreement with the proposal, which is depicted in the
sketch of Figure 9, that the limiting step of the overall catalytic process is the FAD releasing step. This
hypothesis has been previously put forward on the bases of steady-state kinetics and cofactor release
dynamics in the case of isoform 2 [17,23].
The described changes at the molecular level only affect the active site and its relationships with
the cofactor. Indeed, other typical features of the enzyme, such as the inhibition by GTP is similar to
the FADS WT enzymes [22,23]. Interestingly, NADH, but not NAD, inhibits the rate of FAD synthesis,
thus suggesting an interconnection between the two cofactors and the ability to discriminate between
the redox state of nicotinamide pool. The discrimination may be related to the positive charge of
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the nicotinamide ring. The same features were demonstrated with isoform 2; when measuring FAD
hydrolase activity NADH is also substrate of FADHy domain [20].
Again, the response to the SH binding reagent HgCl2, is not affected by the mutation, correlating
with the previous finding that the SH sensitive residue(s) are not in close proximity to the active
site [18]. This phenomenon of kcat increases also introduces important perspectives in human health.
The hFADS6 has been previously described as an “emergency protein” on the basis of its expression in
patients with FADS gene defects [7] and of its functional and biochemical characterization [21]. In these
patients, a decrease of FAD synthesis is the cause of the pathological alterations. Thus, the knowledge
of a strategy to increase the reaction rate, i.e., the capacity of synthesizing FAD, of the emergency
protein hFADS6, could open the possibility to ameliorate therapeutic interventions. As an example,
targeting the D238 residue by specific chemical reagents (drugs) that reduce the hydrophilic property
of this residue could partly mimic the effect of the mutation. Chemical screening and further mutations
are under investigation to find conditions for further increasing the FAD synthesis rate of hFADS6.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 12 of 17 
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Figure 9. Sketch of the catalytic cycle of FAD synthases. In the figure the schematic representation of
FAD synthesis performed by hFADS6 (orange boxes) or hFADS6-D238A (blue boxes), and next cofactor
delivery to client apo-flavoprotein (green boxes). Both recombinant proteins show the same catalytic
cycle, in addition, several differences are highlighted in the picture: in the mutant, the increased
Kms for substrates ATP and FMN (in the forward reaction) and PPi and FAD (in the reverse reaction)
are highlighted by increasing font size; the increased kcat in the mutant is highlighted by decreasing
arrow length in the last step from the enzyme-FAD (E-FAD) complex to free enzyme (E); the increased
ability, in the mutant, to deliver the cofactor to client apo-flavoprotein is highlighted by decreasing
arrow length from the enzyme-FAD (E-FAD) complex to product FAD. This picture is based on results
obtained with the isoform 2 in [17] and with D238A-hFADS6 in this work.
4. Materials and Methods
4.1. Materials
All chemicals were from Sigma-Aldrich (St. Louis, MO, USA), unless otherwise specified. The
Escherichia coli Rosetta(DE3) strain was purchased from Novagen (Madison, WI, USA). Restriction
endonucleases and o her cloning reagents were purchased from Fermentas (Glen Burnie, MD, USA).
Chelating Seph rose Fast Fl w was from Am sham Bio ciences (Arlington Heights, IL, USA), and the
Isolate II PCR and Gel Kit (Bioline, London, UK). The dye reagent for protei assay was from Bio-Ra
(Hemel Hempstead, Herts, UK).
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4.2. Site-Directed Mutagenesis of the hFADS6
The hFADS6-D238A mutant was obtained by PCR overlap extension method [18] using as forward
and reverse mutagenic primers 5′-TTCAGCCCCACTGCTCCAGGCTGGCCCGCATTCAT-3′ and
5′-ATGAATGCGGGCCAGCCTGGAGCAGTGGGGCTGAA-3′, respectively. The external forward
and reverse wild type primers allowed the directional cloning of the desired hFADS6-D238A cDNA
between EcoRI (at 5′ end) and XhoI (at 3′ end) restriction sites of the pH6EX3 expression vector. The
resulting recombinant protein carried the extra N-terminal sequence MSPIHHHHHHLVPRGSEASNS.
4.3. Expression of the WT hFADS6 and hFADS6-D238A Proteins in E. coli
Rosetta(DE3) strain was transformed with either pH6EX3-hFADS6 or pH6EX3-hFADS6-D238A
plasmids by calcium chloride treatment. Selection of transformed colonies was performed on LB-agar
plates containing 100 µg/mL ampicillin and 34 µg/mL chloramphenicol. E. coli Rosetta(DE3) cells
carrying the recombinant plasmids were inoculated in 10 mL of LB medium (1% tryptone, 0.5% yeast
extract, 0.5% NaCl, pH 7.0) supplemented with 100 µg/mL ampicillin and 34 µg/mL chloramphenicol,
and cultured overnight at 37 ◦C with rotary shaking (~180 rpm). The day after, a 5 mL aliquot of the cell
culture was transferred to 0.5 L of fresh LB medium supplemented with antibiotics and grown at 37 ◦C
to A600 equal to 0.8 to 1. Then, 0.5 mM IPTG was added to induce the expression of the recombinant
WT and mutant proteins. Growth was continued overnight at 20 ◦C, bacteria were harvested by
centrifugation at 3000× g for 10 min at 4 ◦C and the pellets stored at −20 ◦C. The bacterial pellet (about
4 g wet weight) was thawed on ice and resuspended in 30 mL start buffer (500 mM NaCl, 40 mM
HEPES/Na, pH 7.4) supplemented with protease inhibitor cocktail (P8849, Sigma-Aldrich, Merck,
Milan, Italy 1 mL/20 g of cells wet weight) and 0.5 mM phenylmethyl sulfonyl fluoride (PMSF, P7626,
Sigma-Aldrich, Merck, Milan, Italy). Cells were disrupted by mild sonication (one cycle of 10 min and
one cycle of 5 min with 1 s Pulse ON and 1 s Pulse OFF, at 40 W) on ice bath using a VCX-130 Sonifier
(Sonics). The soluble and the insoluble cell fractions were separated by centrifugation of the cell lysate
at 20,000× g for 30 min at 4 ◦C. The supernatant, containing the soluble overexpressed 6His-hFADS6
or 6His-D238A-hFADS6 proteins, was used for SDS-PAGE analysis, FADS activity assay and further
protein purification (see below).
4.4. Purification of Recombinant hFADS6-D238A
A 40 mL aliquot of the soluble cell fraction, obtained from E. coli Rosetta(DE3) strain transformed
with the pH6EX3-hFADS6-D238A plasmid, was applied onto a Chelating Sepharose Fast Flow column
(3.5 mL packed resin), previously charged with 200 mM NiSO4 according to the producer’s protocol,
and equilibrated with the start buffer. The column was first washed with 35 mL start buffer, then,
developed with a step gradient of 50 mM, 100 mM, 250 mM, and 500 mM imidazole in the same buffer.
At each step of the purification procedure, the FADS activity was measured (see below) and the purity
of the proteins was checked by SDS-PAGE. Prior to storing or further processing, fractions containing
the purified recombinant protein were desalted by gel filtration on a PD10 column in 40 mM HEPES/Na,
5 mM β-mercaptoethanol, pH 7.4. These protein samples were stable for at least 30 days at 4 ◦C.
Protein concentration and FAD/protein monomer ratio measurements were carried out as
previously described [21].
4.5. 3D Modeling and Docking of the WT hFADS6 and hFADS6-D238A Proteins
The 3D model of the hFADS6 protein was obtained by ab initio using the server Robetta (available
at http://robetta.bakerlab.org/) as previously described [21]. FAD was docked in the same position
as in the 3G6K structure by aligning the two structures with the MatchMaker tool of the Chimera
software using Needleman-Wunsch algorithm and BLOSUM-62 matrix [28]. D238A mutation in
hFADS6 structure was introduced using a rotamer library according to Shapovalov and Dunbrack [29].
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4.6. Measurements of Enzyme Catalyzed Rates for FAD Synthesis and FAD Pyrophosphorolysis
The rate of FAD synthesis and FAD cleavage were measured in continuo as in [23], by exploiting the
different fluorescence properties of FAD with respect to FMN. Fluorescence time courses (λ excitation
at 450 nm and λ emission at 520 nm) were followed at 37 ◦C in a FP-8300 Jasco spectrofluorometer.
In each experiment, FMN and FAD fluorescence were calibrated by using standard solutions whose
concentrations (used in µM range) were calculated by using ε450 of 12.2 mM−1 cm−1 for FMN and
11.3 mM−1 cm−1 for FAD. Under the experimental condition used here, the specific relative FAD
fluorescence coefficient (φFAD) proved to be about ten times lower than those of FMN (φFMN) [30,31].
For FAD synthesis rate measurements, purified protein fractions (2 to 10 µg, 0.06 to 0.26 nmoL
protein as monomer, unless otherwise indicated) were incubated in 50 mM Tris⁄HCl, pH 7.5, containing
5 mM MgCl2, 3 µM FMN, 100 µM ATP, and additional reagents as appropriate. The rate of FAD
synthesis, expressed as nmoL FAD min−1 mg protein−1, was calculated from the rate of fluorescence
decrease, measured as the tangent to the initial part of the experimental curve by applying the
following equation:
V0 = [(∆F450/520/∆φ450/520) × Vf]/(t ×m) (1)
where ∆F is expressed in fluorescence arbitrary units, ∆φ = φFMN − φFAD is expressed as µM−1, Vf is
expressed in mL, t is time expressed in min, and m is the mass of protein in mg.
The rate of FAD pyrophosphorolysis catalyzed by 6His-D238A-hFADS6 (5 to 10 µg, 0.13 to 0.26
nmoL protein as monomer) was measured in 50 mM Tris⁄HCl, pH 7.5, containing 5 mM MgCl2 in the
presence of 5 mM MgCl2, 1 mM NaPPi (sodium pyrophosphate), and 0.5 µM FAD, unless otherwise
indicated. The rate of FAD cleavage was expressed as nmol FAD min−1 mg protein-1, and was
calculated from the rate of fluorescence increase, measured as the tangent to the initial part of the
experimental curve, as previously described.
In the case of using WT hFADS6, which is a FAD binding protein, the measurement of Km for FAD
might not be accurate. To overcome this limitation, the apo-form of the protein was obtained by a rapid
procedure in the cuvette simply by allowing autocatalytic endogenous bound FAD conversion to FMN
by adding only 1 mM NaPPi. The reaction was followed for about 10 min until endogenous bound
FAD is completely converted to FMN, i.e., the fluorescence does not change. At this stage, external
FAD was added at different concentrations and the dependence of the reaction rate was studied.
4.7. Kinetics for the Binding of Flavinic Ligands to WT hFADS6 and hFADS6-D238A Proteins
Pre-steady-state kinetic experiments were performed using stopped-flow spectroscopy on an
Applied Photophysics SX17.MV spectrophotometer using the Pro-Data SX software (Applied Photophysics
Ltd. Leatherhead, Surrey, UK). The fluorescence of flavins was measured in a continuous assay with an
excitation wavelength of 445 nm, while the emission was recovered using a >530 nm cut-off filter and
the voltage was set to 350 V. Then, 100 nM hFADS6 samples were mixed with samples that contained
increasing concentrations of FMN or FAD (which varied in the range 0.025–1 µM), in the absence and
in the presence of saturating concentrations of their respective co-substrates ATP or PPi (250 µM). All
the indicated concentrations are final ones in the stopped-flow observation cell. Measurements were
carried out at 25 ◦C in 50 mM HEPES/NaOH, 10 mM MgCl2, pH 7.0, 5 mM β-mercaptoethanol. At
least three reproducible kinetic traces of changes in fluorescence were recorded for each condition and
fitted to exponential equations (usually one or two exponentials were used)
y =
∑
Aie−kobs,it (2)
where Ai and kobs,i represent the amplitude and the observed rate constant, respectively, for each of the
processes (i) that contribute to the overall time-dependent fluorescence change for each experimental
condition. Processes whose kobs showed a linear dependence on flavin concentration were fit to a
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one-step model that accounts for the kinetic equilibrium of the formation and dissociation of the
protein-flavin complex, whose kinetics can be represented by
kobs = kon[FLV] + koff (3)
where kon and koff are the kinetic constants for complex formation and dissociation, respectively.
4.8. Isothermal Titration Calorimetry (ITC)
Measurements were carried out using an Auto-ITC200 microcalorimeter (MicroCal LLC,
Northampton, MA, USA) thermostated at 25 ◦C. Ligand (100 µM FMN or FAD) and proteins (~15
µM) were dissolved in 50 mM HEPES/NaOH, 10 mM MgCl2, pH 7.0, 2 mM β-mercaptoethanol, and
degassed prior to titration. Up to 19 injections of 2 µL of ligand were added to the sample cell (~0.2
mL) containing the enzyme and then mixed via the rotating (1000 rpm) stirrer syringe. Since either no
binding or slow binding was detected, data fitting to obtain thermodynamic binding parameters was
not reliable.
4.9. Electrophoretic Analysis
Proteins were separated by SDS-PAGE on 12% total polyacrylamide gels, according to Laemmli [32].
Quantitative evaluation of Coomassie blue-stained protein bands was carried out using the Chemidoc
imaging system and the Quantity One software (Bio-Rad), as described previously [33].
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/24/
6203/s1.
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Abbreviations
FADS FAD synthase
FMNAT FMN adenylyl transferase
hFADS6 human FAD synthase isoform 6
Rf riboflavin
FMN flavin mono nucleotide
FAD flavin adenine dinucleotide
PAPS phosphoadenosine 5-phosphosulfate
FADSy FAD synthase domain
MPTb molybdopterin binding
FADHy FAD hydrolase domain
BVVLS Brown–Vialetto-van Laere syndrome
RR-MADD
PMSF
riboflavin responsive multiple acyl-CoA dehydrogenase deficiency
phenylmethyl sulfonyl fluoride
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